Sector News

Merck buys I-O biotech Rigontec

September 6, 2017
Life sciences

Merck is spending €115 million ($137 million) up front and up to €349 million in future payments to buy out German biotech Rigontec.

The Munich, Germany-based company is at work on accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a new approach in cancer immunotherapy.

The idea is to induce both immediate and long-term antitumor immunity; its leading candidate, RGT100, is in early clinical trials in patients with various tumors. More details on targets and financials were not given.

The early-stage company was founded back in 2014 as a spinout of the University Bonn in Germany, raising nearly €30 million in that time from a host of VCs, including Boehringer’s Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds, Wellington Partners Life Sciences and MP Healthcare Venture Management.

Though not on the scale of Gilead’s recent $11.9 billion buyout of CAR-T biotech Kite Pharma, Merck hopes this can add to its pipeline of cancer meds in a broader effort to shore up its future in I-O, coming after the commercial success of its checkpoint inhibitor Keytruda, which now has a series of FDA-approved uses across a number of cancers.

By Ben Adams

Source: Fierce Biotech

Related News

October 17, 2020

Ong leaves Biogen to become CEO-partner at Flagship

Life sciences

The appointment makes Tuyen Ong the latest in a series of new CEO-partners hired by Flagship. Flagship Pioneering has named Tuyen Ong as CEO-partner. The new role sees the ex-Biogen […]

October 17, 2020

Pharma, take note: Millennials plan to spend more on meds, study says

Life sciences

The COVID-19 pandemic has millennials worried—and that has them planning to buy more prescription drugs in the future, new research finds. WPP’s global media group, Mindshare, began surveying consumers in […]

October 17, 2020

AstraZeneca secures $486m from US for Covid-19 antibody

Life sciences

AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment. AstraZeneca has received an investment […]